Jain Global’s Capricor Therapeutics CAPR Stock Holding History

Jain Global’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,700	Closed	-$626K	–	1249
2025 Q4	$626K	Buy	+21,700	New	+$283K	﹤0.01%	790

Other funds holding CAPR

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JHC

Jones Hill Capital New York $470M AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Jain Global's CAPR Position: Q1 2026 in Review

Jain Global sold out of Capricor Therapeutics (CAPR) in Q1 2026, closing a stake of 21,700 shares — an estimated $626K sold.

Jain Global first reported a position in CAPR in Q4 2025 and held it in 1 quarter. The position peaked at $626K in Q4 2025. 177 funds tracked by Wall St. Rank hold CAPR as of Q1 2026.

Jain Global reported no remaining Capricor Therapeutics position as of Q1 2026 after selling out during the quarter.
Jain Global sold 21,700 Capricor Therapeutics shares in Q1 2026, an estimated $626K.
Jain Global first reported a position in Capricor Therapeutics in Q4 2025 and held it in 1 quarter.
Jain Global's Capricor Therapeutics position peaked at $626K in Q4 2025.
177 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2026.

Based on Jain Global's 13F filing for Q1 2026, filed 15 May 2026.